Background & DR-TB Treatment Principles
- Multidrug-Resistant Tuberculosis (MDR-TB: resistance to Isoniazid and Rifampicin) and Rifampicin-Resistant TB (RR-TB) historically carried cure rates $<50–60\%$ under 18 to 24-month regimens containing injectable aminoglycosides (Kanamycin, Amikacin) that caused irreversible ototoxicity.
- The BPaLM Regimen: An all-oral 6-month (26-week), four-drug regimen consisting of Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin.
- BPaL Regimen: If fluoroquinolone resistance is documented (Pre-XDR TB), Moxifloxacin is dropped, continuing with the 3-drug BPaL combination.
- Landmark Evidence (TB-PRACTECAL Trial, NEJM 2022):
- Phase 2/3 randomized controlled trial comparing BPaLM against older standards of care.
- Cure rate was $89\%$ in the BPaLM arm vs $52\%$ in the standard care arm ($p<0.001$).
- Dramatically fewer adverse events and zero treatment-related deafness.
Pharmacological Profile Of Regimen Components
| Drug | Class & Mechanism | Key Characteristics & Pediatric Considerations |
|---|---|---|
| Bedaquiline (Bdq) | Diarylquinoline; specifically inhibits mycobacterial ATP synthase | Bactericidal and sterilizing against dormant and active bacilli. Dispersible 20 mg tablets available for pediatric dosing. |
| Pretomanid (Pa) | Nitroimidazooxazine; blocks mycolic acid synthesis & releases reactive nitric oxide anaerobically | First developed by TB Alliance; currently indicated in adolescents $\ge 14\text{ years}$. |
| Linezolid (Lzd) | Oxazolidinone; inhibits protein synthesis at 23S ribosomal RNA subunit | Highly potent sterilizing drug; dose- and duration-dependent mitochondrial toxicity (myelosuppression, neuropathy). |
| Moxifloxacin (Mfx) | 4th generation fluoroquinolone; inhibits DNA gyrase and topoisomerase IV | Omitted if FQ resistance (Pre-XDR) is detected on Second-Line Line Probe Assay (SL-LPA) or phenotypic DST. |
DR-TB Regimen Selection Pathway (NTEP & WHO 2024)
flowchart TD
A["Confirmed Rifampicin-Resistant / MDR-TB<br>(via Truenat / CBNAAT)"] --> B["<b>Perform Fluoroquinolone DST / SL-LPA</b><br>Assess Age and Extent of Disease"]
B --> C{"Age ≥ 14 Years &<br>Non-Severe / Pulmonary?"}
C -->|"Yes, FQ-Sensitive"| D["<b>BPaLM Regimen (6 Months Oral)</b><br>• Bedaquiline + Pretomanid + Linezolid (600 mg) + Moxifloxacin<br>• Duration: 26 weeks under DOT / direct supervision"]
C -->|"Yes, FQ-Resistant (Pre-XDR)"| E["<b>BPaL Regimen (6 Months Oral)</b><br>• Bedaquiline + Pretomanid + Linezolid (600 mg)<br>• Moxifloxacin omitted"]
C -->|"No (Children < 14 Years)"| F["<b>Pediatric All-Oral DR-TB Regimen (9–18 Months)</b><br>• <b>Bedaquiline (20 mg DT)</b> and/or <b>Delamanid (25 mg DT)</b><br>• + Linezolid + Clofazimine + Levofloxacin<br>• 100% Injectable-Free"]
D --> G["Monthly ECG (QTcF) + Monthly CBC (Anemia/Plat) + LFTs"]
E --> G
F --> G
Dosing And Administration
1. Adolescents Aged $\ge 14$ Years (BPaLM / BPaL)
Administered with meals for 26 continuous weeks (6 months):
- Bedaquiline: $400\text{ mg}$ once daily for weeks 1–2 (loading dose), then $200\text{ mg}$ three times weekly (with at least 48 hours between doses) for weeks 3–26.
- Pretomanid: $200\text{ mg}$ once daily for 26 weeks.
- Linezolid: Initiated at $600\text{ mg}$ once daily.
- If peripheral/optic neuropathy or significant myelosuppression develops, reduce dose to $300\text{ mg}$ daily or interrupt temporarily.
- Mandatory co-administration of Pyridoxine (Vitamin B6) $50–100\text{ mg/day}$.
- Moxifloxacin: $400\text{ mg}$ once daily for 26 weeks (in BPaLM only).
2. Children Under 14 Years: All-Oral Child-Friendly Regimens
- Pretomanid is currently undergoing pediatric pharmacokinetic evaluation in trials (e.g., IMPAACT 2034, BEAT-India).
- Therefore, for children $<14$ years, NTEP and WHO utilize Bedaquiline (approved down to age 0 / infants) and Delamanid (approved down to age 0 / infants) combined with Linezolid, Clofazimine, and Levofloxacin:
- Dispersible Bedaquiline (20 mg DT): Allows precise weight-band dosing in infants and young children.
- Dispersible Delamanid (25 mg DT): Can be safely combined with Bedaquiline under careful cardiac monitoring.
Key Safety And Monitoring Checklist
- QTcF Prolongation (ECG Monitoring):
- Both Bedaquiline and Moxifloxacin block cardiac HERG potassium channels, prolonging the QT interval.
- Obtain baseline ECG, then repeat at weeks 2, 4, 8, 12, 16, and 24.
- If $\text{QTcF} > 500\text{ ms}$: Immediately discontinue offending agents, check serum potassium, magnesium, and calcium, and perform serial repeat ECGs.
- Linezolid Hematologic & Neurologic Toxicity:
- Inhibits mitochondrial ribosomes, causing dose-dependent bone marrow suppression (pure red cell aplasia, thrombocytopenia) and peripheral / optic neuropathy.
- Monitor CBC monthly. If hemoglobin drops by $\ge 2\text{ g/dL}$ or platelets $<50,000/\mu\text{L}$, reduce dose to $300\text{ mg}$ or pause linezolid until counts recover.
- Hepatotoxicity:
- Monitor baseline LFTs, then monthly. Withhold regimen if transaminases $>5\times$ upper limit of normal or $>3\times$ ULN with symptoms of jaundice.